|Expert opinion on therapeutic targets (2007) 11:695-705|
|Northeast Structural Genomics Consortium|
(click to unfold)
Nicotinamide adenine dinucleotide (NAD(+)) has crucial roles in many cellular processes, both as a coenzyme for redox reactions and as a substrate to donate ADP-ribose units. ...
Enzymes involved in NAD(+) metabolism are attractive targets for drug discovery against a variety of human diseases, including cancer, multiple sclerosis, neurodegeneration and Huntington's disease. A small-molecule inhibitor of nicotinamide phosphoribosyltransferase, an enzyme in the salvage pathway of NAD(+) biosynthesis, is presently in clinical trials against cancer. An analog of a kynurenine pathway intermediate is efficacious against multiple sclerosis in an animal model. Indoleamine 2,3-dioxygenase plays an important role in immune evasion by cancer cells and other disease processes. Inhibitors against kynurenine 3-hydroxylase can reduce the production of neurotoxic metabolites while increasing the production of neuroprotective compounds. This review summarizes the existing knowledge on NAD(+) metabolic enzymes, with emphasis on their relevance for drug discovery.
|metabolism physiology therapeutic use drug therapy drug effects antagonists & inhibitors pharmacology |
|Humans Animals Signal Transduction Adenosine Diphosphate Ribose NAD Drug Design DNA Damage Mice Enzyme Inhibitors Tryptophan Neurodegenerative Diseases Acrylamides Aging Antineoplastic Agents Autoimmune Diseases Clinical Trials, Phase II as Topic Cyclic ADP-Ribose Kynurenine Neoplasms Neuroprotective Agents Piperidines Poly Adenosine Diphosphate Ribose Sirtuins |
|106 (Last update: 01/12/2019 3:37:36pm)|